SGLT2 Inhibitor Luseogliflozin (TS-071) Protects from Diabetic Nephropathy in an Animal Model of Type 2 Diabetes.

Yumi Takiyama, Bessho R, Maeda Manami, Kuralay Atageldiyeva, Tsuyoshi Yanagimachi, Jun Honjo, Yukihiro Fujita, Atsuko Abiko, Yuichi Makino, Masakazu Haneda

Research output: Chapter in Book/Report/Conference proceedingConference contribution

Original languageEnglish
Title of host publicationSGLT2 Inhibitor Luseogliflozin (TS-071) Protects from Diabetic Nephropathy in an Animal Model of Type 2 Diabetes.
PublisherAmerican Diabetes Association Inc.
PagesA136-A136
Publication statusPublished - Jun 2014

Cite this

Takiyama, Y., R, B., Manami, M., Atageldiyeva, K., Yanagimachi, T., Honjo, J., Fujita, Y., Abiko, A., Makino, Y., & Haneda, M. (2014). SGLT2 Inhibitor Luseogliflozin (TS-071) Protects from Diabetic Nephropathy in an Animal Model of Type 2 Diabetes. In SGLT2 Inhibitor Luseogliflozin (TS-071) Protects from Diabetic Nephropathy in an Animal Model of Type 2 Diabetes. (pp. A136-A136). American Diabetes Association Inc..